Stryker nominates new board member

PORTAGE, Michigan - Stryker Corporation (NYSE:SYK), a global leader in medical technologies, has announced the nomination of Emmanuel "Manny" Maceda to its board of directors, with the election set for the upcoming Annual Meeting of Shareholders on May 8, 2025. Maceda, currently the Chairman of Bain & Company, brings over three decades of experience in guiding top-tier organizations through significant transformations.

Manny Maceda’s professional background includes a notable tenure as the Worldwide Managing Partner and CEO of Bain & Company from 2018 to 2024. During his leadership, he spearheaded the firm’s strategic and operational growth across its global offices, emphasizing digital innovation, sustainability, and maintaining the company’s recognized culture. Maceda’s career at Bain, which began in 1989, has been marked by various senior roles where he advised CEOs from multiple industries on strategic initiatives aimed at growth, cost management, and organizational effectiveness.

Maceda holds a Master of Science in Management from the MIT Sloan School of Management, where he is an advisory board member, and a Bachelor’s degree in Chemical Engineering with High Honors from the Illinois Institute of Technology.

Kevin Lobo, Chair and CEO of Stryker, expressed enthusiasm about the potential addition of Maceda to the board, citing his strategic insight, global leadership experience, and proven success in corporate transformation as valuable assets that will contribute to Stryker’s growth and shareholder value.

Stryker is known for its commitment to improving healthcare through its diverse range of products and services in MedSurg, Neurotechnology, and Orthopaedics. The company’s mission is to work alongside healthcare professionals globally to impact patient care, touching the lives of over 150 million patients annually. With a 35-year track record of consistent dividend payments and 15 consecutive years of dividend increases, Stryker demonstrates strong financial stability. For deeper insights into Stryker’s performance and future prospects, including exclusive ProTips and comprehensive valuation metrics, visit InvestingPro, where you’ll find detailed analysis in our Pro Research Report.

The information in this article is based on a press release statement from Stryker Corporation.

In other recent news, Stryker Corporation has reported several key developments. The company completed its acquisition of Inari Medical, which has led to adjustments in financial forecasts. Although the acquisition is expected to slightly dilute Stryker’s operating margin and earnings per share in 2025, Needham analysts have raised their revenue estimates for the coming years, indicating a positive long-term impact. RBC Capital Markets maintained an Outperform rating for Stryker, highlighting the company’s strong performance and resilience amid economic challenges. Stryker’s management conveyed optimism about maintaining high procedure volumes and a robust order book, suggesting a promising outlook for 2025. Piper Sandler also reaffirmed a positive stance, projecting strong growth rates for Stryker within the medtech sector, supported by market share gains and increased procedure volumes. Additionally, Stryker has introduced the Steri-Shield 8 personal protection system and the Sync Badge communication device, showcasing its commitment to innovation in medical technology. These product launches aim to enhance safety and efficiency in healthcare settings, reflecting Stryker’s ongoing efforts to support healthcare professionals and improve patient care.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.